What is PreludeDx?
Founded in 2009 and leveraging technology licensed from the University of California San Francisco, PreludeDx is at the forefront of personalized breast cancer diagnostics. The company is dedicated to serving breast cancer patients and physicians globally by developing precision tools designed to impact treatment decisions. PreludeDx's core mission is to deliver innovative technologies that not only enhance patient outcomes but also contribute to mitigating the overall financial burden on the healthcare system. This focus positions PreludeDx as a key player in the evolving landscape of cancer care.
How much funding has PreludeDx raised?
PreludeDx has raised a total of $20.4M across 2 funding rounds:
Debt
$350K
Other Financing Round
$20M
Debt (2020): $350K with participation from PPP
Other Financing Round (2022): $20M led by Evidity Health Capital
Key Investors in PreludeDx
Evidity Health Capital
Evidity Health Capital is a venture capital and growth equity firm specializing in medical devices, in vitro diagnostics, and digital health, focusing on providing growth capital to commercialized companies.
PPP
Public-Private Partnership
What's next for PreludeDx?
With a substantial enterprise-level funding round, PreludeDx is poised for accelerated growth and further development of its precision diagnostic technologies. The recent strategic investment signals confidence from backers in the company's trajectory and its potential to disrupt the breast cancer diagnostics market. Future endeavors will likely involve scaling operations, expanding market reach, and continuing research and development to refine its product offerings. This capital infusion is expected to bolster PreludeDx's capacity to deliver impactful solutions to patients and healthcare providers, solidifying its position as a leader in personalized oncology.
See full PreludeDx company page
